Catalog record · Compliance & Regulatory
Stage as of source date not established · historical report, not live reconfirmation.
Roche clinical-study-report drafting
Primary workflow source. A named organization's workflow supported by a reviewed primary source. Stage is reported separately; this label does not establish measured outcomes or independent validation.
Last researched Oct 26, 2026. Source access and reported stage are recorded below; deployment evidence does not establish ROI.
What the research supports
Roche's conference presentation identifies GenCSR among internal AI applications, generating CSR drafts from protocols and tables.
- Reported stage
- Production
- Technology
- GenAI/LLM
- Business function
- Back Office
- Impact (legacy label)
- Not labeled
- Catalog date · unconfirmed
- Not reported
- Imported
- Oct 29, 2026
- Last researched
- Oct 26, 2026
Measures & evidence
No quantified measure recorded. This is a gap in the evidence, not a finding of no value.
Documented vendor relationships
No vendor relationship has been linked to this specific workflow in the curated overlay. This does not mean it was built without vendors.
See the company’s documented relationshipsDeployment evidence & limits
Presentation's AI-use-at-Roche section describes internal implementation and names the document-generation application. Status date not established.
Stage is as reported in the cited evidence. Current operating status has not been independently reconfirmed; the research date is an editorial review date.
Primary evidence is a Roche employee conference deck hosted by a professional forum, not an audited deployment study; precise scope/date/volume unavailable. A conference statement does not prove regulatory submission approval, scale or end-to-end time savings; require reviewable provenance.
Potential FS application · inferred
Inferred: Draft model-development and validation reports from approved protocols, test plans and results tables.
Reuses known study design and evidence tables to produce structured technical documentation.
Original industry: Pharmaceuticals and biotechnology. Transfer limits: A conference statement does not prove regulatory submission approval, scale or end-to-end time savings; require reviewable provenance.
Recorded dependencies
- Traceable source data and approved document/control schemas
- Qualified human review and local testing of accuracy, omissions and full workflow effort
Source register
- Bioanalysis 2.0: Navigating the AI Frontiere-b-f.eu · opens in a new tab
European Bioanalysis Forum (Roche author presentation) · issuer · full-text · Publication date not recorded
Research lanes: health_life_sciences · Batch global-discovery-2026-10-26. Coverage and remaining gaps